Drugs / LMP2 Antigen-specific TCR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03925896 | Aug 2019 → Aug 2020 | nasopharyngeal carcinoma | Sun Yat-sen University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMP2 Antigen-specific TCR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03925896 ↗ |
| Modality | Cell therapy | “EBV TCR-T cells” NCT03925896 ↗ |